ReviewCancers2020
Potential Mechanisms of Cancer-Related Hypercoagulability.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Clinical Outcomes and Prognostic Implications of TAVR in Patients With Active Cancer: A Meta-Analysis.Clinical cardiology · 2025Pooled it
- The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Cerebral Venous Sinus Thrombosis Revealing ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Inherited Thrombophilia and Concomitant Infection: Case Report and Narrative Review.Life (Basel, Switzerland) · 2026Article
- Persistent Hypercoagulability After Radical Prostatectomy: Biomarker Dynamics and Implications for Individualized Thromboprophylaxis.Journal of clinical medicine · 2026Review
- Pulmonary Embolism in Patients with Lung Cancer: Incidence and Performance of Prognostic Markers.Cancers · 2026Article
- Mitochondrial IκBα fuels cancer progression through metabolic rewiring, endothelial activation, and thrombotic spread.Cell death discovery · 2026Article
- Arterial Thrombosis in Severe Ulcerative Colitis: A Case-Based Narrative Review of Current Evidence.Biomedicines · 2026Review
- Cardiopulmonary Complications in Obese Patients with Gynecologic Cancer: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Blood DNA methylation-predicted plasma protein levels and colorectal cancer survival.Clinical epigenetics · 2026Article
- Associated factors and predictive modeling of deep vein thrombosis in stroke patients undergoing rehabilitation.Frontiers in neurology · 2026Article
- Prediction of acute postoperative protein depletion risk in colon cancer using an in-context learning foundation model: a retrospective cohort study.Frontiers in oncology · 2026Article
- Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life.Nature medicine · 2025Observational
- Effect of cardiovascular risk factors on overall survival in postoperative patients with esophageal squamous cell carcinoma: a retrospective cohort analysis.Journal of thoracic disease · 2025Article
- Venous thromboembolism and cancer risk in patients with a history of migraine: a population-based cohort study.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- Visceral adipose tissue is associated with occult synchronous peritoneal metastasis in colorectal cancer.Pleura and peritoneum · 2025Article
- Primary Ewing sarcoma of renal origin with tumor thrombus into inferior vena cava: a case report.Journal of medical case reports · 2025Article
- Bone Metastasis Mediates Poor Prognosis in Early-Onset Gastric Cancer: Insights Into Immune Suppression, Coagulopathy, and Inflammation.Cancer medicine · 2025Article
- A management of a patient with chronic thromboembolic pulmonary hypertension prior to surgical resection for lung cancer.Respiratory medicine case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between cancer and thrombosis has been known for over a century and a half. However, the mechanisms that underlie this correlation are not fully characterized. Hypercoagulability in cancer patients can be classified into two main categories: Type I and Type II. Type I occurs when the balance of endogenous heparin production and degradation is disturbed, with increased degradation of endogenous heparin by tumor-secreted heparanase. Type II hypercoagulability includes all the other etiologies, with factors related to the patient, the tumor, and/or the treatment. Patients with poor performance status are at higher risk of venous thromboembolism (VTE). Tumors can result in VTE through direct pressure on blood vessels, resulting in stasis. Several medications for cancer are correlated with a high risk of thrombosis. These include hormonal therapy (e.g., tamoxifen), chemotherapy (e.g., cisplatin, thalidomide and asparaginase), molecular targeted therapy (e.g., lenvatinib, osimertinib), and anti-angiogenesis monoclonal antibodies (e.g., bevacizumab and ramucirumab).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.